ARCHIVES

FDA Delays NDA On BCNU, But New Drug Seminar Still Scheduled

This article is from The Cancer Letter archive.

Vol. 01 No. 48 | November 28, 1975

Download PDF Visit The Full Archive

Related Articles

ACS Endorses Clinton Health Care Reform, Wit qualifications

March 11, 1994

Reinventing NCI: clinical Trials report Calls for Study Section, increased Funding For Cooperative Groups

October 3, 1997

Evidence “Weak” Linking EMFs, cancer

June 25, 1999

Hammond Resigns As Director Of USC Comp Center

May 29, 1981

Capizzi Succeeds Spurr as Director Of Bowman Gray Cancer Center

September 10, 1982

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007